 Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 3 | 2 | 5 | | 2007 | 3 | 1 | 4 | | 2008 | 3 | 3 | 6 | | 2009 | 5 | 3 | 8 | | 2010 | 3 | 4 | 7 | | 2011 | 10 | 4 | 14 | | 2012 | 5 | 3 | 8 | | 2013 | 6 | 2 | 8 | | 2014 | 7 | 2 | 9 | | 2015 | 5 | 1 | 6 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 4 | 5 | | 2018 | 3 | 3 | 6 | | 2019 | 4 | 0 | 4 | | 2020 | 2 | 2 | 4 | | 2021 | 2 | 3 | 5 | | 2022 | 2 | 2 | 4 | | 2023 | 3 | 5 | 8 | | 2024 | 1 | 0 | 1 | | 2025 | 1 | 0 | 1 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Ornelas A, Countess JA, Kim JY, Cohen RH, Gomez BD, Roer RL, Minhajuddin F, Yenugudhati Vijaya Sai K, Zhou L, Dunn JLM, Chandler C, Reigan P, Cartwright IM, Hall CHT, Bhagavatula G, Onyiah JC, Dowdell AS, Colgan SP. Metabolite mimicry identifies butyrate analogs with select protective functions in the intestinal mucosa. Proc Natl Acad Sci U S A. 2026 Apr 14; 123(15):e2527863123.
-
Votruba KL, Rozwadowski M, Braun T, Rahrig A, Peres E, Williams KM, Fabrizio V, Talano JA, Kitko CL, Parnell N, Reddy P, Choi SW. Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant. Pediatr Blood Cancer. 2026 Jun; 73(6):e70259.
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
-
Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, Binns CA, MacBeth M, Whitty PA, Diamond JR, Pitts TM. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis. Breast Cancer Res. 2024 03 01; 26(1):35.
-
Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024 Jan; 103(1):105-116.
-
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023 10 24; 7(20):6339-6350.
-
Chen CN, Hajji N, Yeh FC, Rahman S, Ali S, Wharton J, Baxan N, Zhao L, Xie CY, Chen YG, Frid MG, Chelladurai P, Pullamsetti SS, Stenmark KR, Wilkins MR, Zhao L. Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology. Am J Respir Crit Care Med. 2023 Oct 15; 208(8):879-895.
-
Robinson EL, Bagchi RA, Major JL, Bergman BC, Matsuda JL, McKinsey TA. HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance. J Clin Invest. 2023 10 02; 133(19).
-
Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy. Front Immunol. 2023; 14:1260545.
-
Zhang H, D'Alessandro A, Li M, Reisz JA, Riddle S, Muralidhar A, Bull T, Zhao L, Gerasimovskaya E, Stenmark KR. Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension. Vascul Pharmacol. 2023 04; 149:107157.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|